PTC Therapeutics (PTCT) has provided an announcement.
PTC Therapeutics, Inc. faces a setback as the European Medicines Agency’s committee has recommended against renewing the conditional marketing authorization for their product TranslarnaTM (ataluren). Despite the negative opinion, the company remains proactive and intends to request a re-examination in accordance with the agency’s guidelines. This development could be significant for investors tracking PTC Therapeutics’ market movements and product approvals in Europe.
Learn more about PTCT stock on TipRanks’ Stock Analysis page.
